Dr Reddy’s Q2 Profit Falls 36% As Lower Lenalidomide Sales Hit US Business

Dr. Reddy’s Laboratories reported a 36% year-on-year decline in profit attributable to equity holders at ₹925 crore in Q2 FY27, as lower lenalidomide sales weighed on its North American business. Revenue declined 1.5% to ₹8,671 crore, while EBITDA margin fell to 20.6% from 26.7% a year earlier. The company said its underlying base business continued to deliver double-digit growth across businesses, excluding Europe and APIs. Business Today TV speaks to M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, on the quarterly performance, semaglutide supplies, growth opportunities and the outlook for its key markets.